Back To: Home : Featured Technology : Multiplex Immunoassay

CLICK HERE FOR WHAT'S NEW IN:
 

Rapid, multiplex detection of validated tumor markers
August 2008
SHARING OPTIONS:

EMD Chemicals

To accelerate the progress of cancer drug discovery and preclinical studies, EMD (the North American affiliate of Merck KGaA, Darmstadt, Germany) in partnership with Rules Based Medicine (RBM), has released the first of a series of new WideScreen Biomarker Assay Kits. These multiplex immunoassays, for the Luminex xMAP Technology platform, utilize technologies that have been validated by RBM in its HumanMAP and RodentMAP service platform. WideScreen Human Cancer Panel 1 can be used to detect six critical tumor biomarkers in human serum, plasma, or tissue culture supernatant samples. These biomarkers were carefully chosen to serve as sensitive, and specific indicators of a variety of tumors. Biomarkers detected in the WideScreen Human Cancer Panel 1 are: alpha-fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), and prolactin. The kit includes all reagents, controls, and buffers needed to perform 96 tests. For more information, see www.novagen.com/widescreen.

EMD Chemicals
800-854-3417
www.emdchemicals.com

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.